Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 5Colitis 2Takayasu Arteritis 1Skin Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Inflammation 1Hepatitis 1Hematologic Neoplasms 1Fatigue 1Drug-Related Side Effects and Adverse Reactions 1Depressive Disorder, Major 1Depression 1Cognitive Dysfunction 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Breast Neoplasms 1Breast Carcinoma In Situ 1Anorexia 1Anemia 1

Interventions

Amifostine 10Cisplatin 8Radiotherapy 7Etoposide 6Cyclophosphamide 4Carboplatin 4Paclitaxel 3pegfilgrastim 2camrelizumab 2apatinib 2Mitoxantrone 2Filgrastim 2Drug Therapy 2Cytarabine 2sodium thiosulfate 1sargramostim 1pazopanib 1icotinib 1glucarpidase 1etoposide phosphate 1denileukin diftitox 1Vitamin E 1Triptorelin Pamoate 1Tocopherols 1Thiotepa 1Tegafur 1Taxes 1Surgical Procedures, Operative 1Silymarin 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Drug-Related Side Effects and Adverse Reactions × Infliximab × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡